Acute myeloid leukemia with 11q23 abnormalities
MONDO:0020317An acute myeloid leukemia associated with t(9;11)(p22.3;q23.3) and MLLT3-KMT2A fusion protein expression. Morphologically it usually has monocytic features. It may present at any age but it is more commonly seen in children. Patients may present with disseminated intravascular coagulation.
Also known as: AML with 11q23 abnormalities, AML with t(9;11)(p22;q23); MLLT3-MLL, acute myeloid Leukaemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A, acute myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A, acute myeloid leukaemia with 11q23 (MLL) abnormalities, acute myeloid leukaemia with MLL abnormalities, acute myeloid leukaemia with t(9;11)(p22.3;q23.3); MLLT3-KMT2A, acute myeloid leukaemia with t(9;11)(p22;q23); MLLT3-MLL
3087 clinical trials for this condition and its sub-types, 11 tagged with Acute myeloid leukemia with 11q23 abnormalities itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New combo therapy shows promise for older leukemia patients
Disease control OngoingThis study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, in 133 older adults (age 60+) with untreated acute myeloid leukemia. The goal was to see how well the treatment could put the cancer into remission and improve survival. The approach uses chemoth…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Precision radiation may boost stem cell transplant success in tough leukemias
Disease control OngoingThis study tests a precise radiation method called total marrow and lymphoid irradiation (TMLI) given with two chemotherapy drugs (etoposide and cyclophosphamide) before a donor stem cell transplant. The goal is to safely deliver higher radiation doses to the bone marrow to wipe …
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a 'Priming' drug boost chemo for tough leukemia?
Disease control OngoingThis phase 2 trial tests whether adding the drug decitabine to standard chemotherapy improves remission rates in adults with acute myeloid leukemia (AML) who have less favorable genetic risk. Decitabine is given before chemo to try to make cancer cells more sensitive. About 178 p…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingThis study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo aims to tame AML in patients too frail for strong chemo
Disease control OngoingThis phase 1 trial tests the combination of nintedanib and azacitidine in older adults with acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy. The goal is to find the safest dose of nintedanib when given with azacitidine and to see how well patients t…
Phase 1 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC